DaltonTx: the intelligence backbone of modern drug discovery

DaltonTX founder team

rethinking the foundations of r&d

Drug discovery today is slower, riskier, and more expensive than it should be. Despite the hype around AI, most platforms still act like biotech companies: trying to build their own drug pipelines instead of enabling pharma at scale. 

DaltonTx was founded to change that. Their vision is bold: to build the intelligence backbone for modern R&D. A platform that integrates seamlessly into pharma workflows, learns with every experiment, and enables agentic scientific reasoning: software that thinks alongside scientists instead of replacing them.

an exceptional founding team

Founded in London by a team with decades of experience across AstraZeneca, Exscientia, and the University of Oxford, DaltonTx combines world-class science with top engineering. The founding team including Dr Garry Pairaudeau, Adrian Rossall, Dr Anthony Bradley, and Professor Charlotte Deane MBE, brings deep expertise in drug discovery, software engineering, and machine learning.

Redefining what AI in pharma means

DaltonTx isn’t trying to be another AI-driven biotech chasing its own pipeline. Instead, the team is building the adaptive infrastructure that the whole industry needs: software that embeds directly into pharma’s daily workflows, supports scientists in real time, and gets smarter with every experiment. By focusing on enablement rather than competition, DaltonTx gives pharma and biotech a lasting capability and an intelligence backbone that makes R&D faster, more efficient, and more reliable. 

from ideas to impact

At its core, DaltonTx generates biological and chemical insight previously out of reach. By combining machine learning with deep domain expertise, DaltonTx creates technology that adapts. This means scientists can design, optimise, and deliver medicines faster while keeping human expertise at the center of the process. “As we combine cutting-edge machine learning with deep drug discovery expertise, we’re creating technology that learns with every experiment and helps scientists turn ideas into impact,” said Professor Charlotte Deane MBE.

backing a new category in drug discovery

We’re delighted to lead DaltonTx’s  £4.1 million seed round, with participation from IQ Capital Partners, Seedcamp, and support from Oxford University Innovation.

“DaltonTx is not just building AI for drug discovery - they’re creating the infrastructure that will power the future of medicine. Their adaptive platform represents a new category in R&D, giving scientists the intelligence backbone needed to transform how breakthrough therapies are discovered and delivered,” said Marc Moesser, Investment Manager at redalpine.

what’s next for DaltonTx

With this new funding, DaltonTx will expand its team in London’s King’s Cross tech and life sciences hub, roll out platform modules that support both small molecules and biologics, and accelerate partnerships with pharma, biotech, and CROs. By building the intelligence backbone of modern drug discovery, DaltonTx is creating the infrastructure for the next wave of medical breakthroughs. We’re proud to back Garry, Adrian, Anthony, Charlotte, and the entire DaltonTx team as they transform how medicines are discovered and delivered.